Physician profile
Jonathan David White
NPI 1376806695
$7,617.45
in general payments reported to CMS, 2019-2025
46 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,621 · 2022: $1,481 · 2023: $1,494 · 2024: $1,568 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,515.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,043.35 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $950.08 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $638.93 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $579.26 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $324.59 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $314.87 | 2021-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $306.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $297.96 | 2021-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $290.22 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $261.05 | 2021-2025 | Gardasil 9, Capvaxive, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.93 | 2021-2024 | Ofev, Jardiance |
| Abbott Laboratories | $216.15 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $203.82 | 2021-2024 | Repatha, Otezla |
| Tolmar, INC. | $173.57 | 2023-2025 | Jatenzo |
| Novartis Pharmaceuticals Corporation | $153.43 | 2022-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.